Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.

Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
International journal of clinical pharmacology research 02/2003; 23(4):129-34.
Source: PubMed

ABSTRACT Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the pathogenesis of diabetic micro- and macrovascular complications via various metabolic derangements. In this review, we discuss the molecular mechanisms of diabetic retinopathy and nephropathy, especially focusing on advanced glycation end products (AGEs) and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in diseases, including diabetic microangiopathy, will be discussed in the next review article.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver disease around the world. It includes a spectrum of conditions from simple steatosis to non-alcoholic steatohepatitis (NASH) and can lead to fibrosis, cirrhosis, liver failure, and/or hepatocellular carcinoma. NAFLD is also associated with other medical conditions such as obesity, diabetes mellitus (DM), metabolic syndrome, hypertension, insulin resistance, hyperlipidemia, and cardiovascular disease (CVD). In diabetes, chronic hyperglycemia contributes to the development of both macro- and microvascular conditions through a variety of metabolic pathways. Thus, it can cause a variety of metabolic and hemodynamic conditions, including upregulated advanced glycation end-products (AGEs) synthesis. In our previous study, the most abundant type of toxic AGEs (TAGE); i.e., glyceraldehyde-derived AGEs, were found to make a significant contribution to the pathogenesis of DM-induced angiopathy. Furthermore, accumulating evidence suggests that the binding of TAGE with their receptor (RAGE) induces oxidative damage, promotes inflammation, and causes changes in intracellular signaling and the expression levels of certain genes in various cell populations including hepatocytes and hepatic stellate cells. All of these effects could facilitate the pathogenesis of hypertension, cancer, diabetic vascular complications, CVD, dementia, and NASH. Thus, inhibiting TAGE synthesis, preventing TAGE from binding to RAGE, and downregulating RAGE expression and/or the expression of associated effector molecules all have potential as therapeutic strategies against NASH. Here, we examine the contributions of RAGE and TAGE to various conditions and novel treatments that target them in order to prevent the development and/or progression of NASH.
    World journal of hepatology. 12/2014; 6(12):880-93.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RESUMEN Las complicaciones vasculares de la diabetes mellitus están representadas por la macroangiopatía y la microangiopatía. La última afecta los pequeños vasos de la retina, los riñones y los nervios periféricos y causa severos daños a los pacientes afectados. En esta revisión se tratan los mecanismos básicos implicados en la microangiopatía, que comprenden la activación de la proteín quinasa C, la formación de los productos finales de la glicosilación avanzada, la reducción de aldosas y el estrés oxidativo. El conocimiento de estos procesos es importante para el diseño de nuevos fármacos que logren prevenir o retrasar el desarrollo de estas complicaciones. ABSTRACT The vascular complications of the diabetes mellitus are represented by macroangiopathy and microangiopathy. The latest affecting the small vessels of the retina, the kidneys, and periferal nerves, causing severe damage of affected patients. In this bibliographical revision, the basic mechanisms implicated in diabetic microangiopathy are treated as examples of the protein kinase C activation, advanced glycation end products, the reduction of aldoses and oxidative stress. It is important for the design of new drugs.
    01/2004; 8(4).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background-An increasing number of studies have demonstrated of that diabetes mellitus (DM) is associated with an increased prevalence of Alzheimer disease (AD), the underlying mechanisms are still obscure. Methods-We developed a streptozotocin (STZ)-induced diabetic AD transgenic mouse model and evaluated the effect of hyperglycemia on senile plaque formation. Results-Our data showed that administration of STZ increased the level of blood glucose and increased the advanced glycation end products (AGEs) in brain tissue, and further enhanced the expression levels of the receptor for AGEs (RAGE) and the nuclear factor-kappa B (NF-κB) in the brain, and accelerated the senile plaque formation in the transgenic mice. Our results showed that STZ-induced insulin-deficient hyperglycemia caused the pathophysiology of AD in APP/PS1 transgenic mice by modulating the AGEs/RAGE/NF-κB pathway. Conclusions-Our study suggests that there is a close linkage of DM and cerebral amyloidosis in the pathogenesis of AD.
    The International journal of neuroscience 11/2013; · 1.53 Impact Factor